EUCTR2013-001912-31-DE进行中（未招募）1 期
Randomised, double-blind, placebo-controlled, multi-centre trial on the efficacy and safety of budesonide for induction of remission in incomplete microscopic colitis - Budesonide for induction of remission in incomplete microscopic colitis
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 106
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Signed informed consent
- •2. Man or woman between 18 and 80 years of age
- •3. Histologically established diagnosis of incomplete microscopic colitis
- •4. History of chronic non-bloody, watery diarrhoea for at least 4 weeks
- •5. Clinically active disease
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 26
排除标准
- •1.Other significant abnormalities in colonoscopy that may have been the cause of diarrhoea except for colonic diverticulosis and non-dysplastic polyps < 2 cm,
- •2.Infectious cause of diarrhoea (local routine stool samples, Clostridium difficile included) or history of infectious diarrhoea within the last 3 months prior inclusion or local intestinal infection,
- •3.Clinical suspicion of drug-induced diarrhoea,
- •4.Prior and present MC (i.e., all histological criteria for collagenous colitis or lymphocytic colitis fulfilled),
- •5.History of bowel resection (except appendectomy, haemorrhoidectomy and endoscopic removal of polyps),
- •6.Radiation therapy of the abdominal or pelvic region,
- •7.Positive antibody titres for celiac disease (tGT IgA + serum IgA), or any known history of celiac disease,
- •8.Untreated active thyroid dysfunction,
- •9.Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder reducing life expectancy,
- •10.Abnormal hepatic function (ALT or ALP > 2.5 x upper limit of normal [ULN]), liver cirrhosis, or portal hypertension,
- •11.Tuberculosis, hypertension, diabetes mellitus, osteoporosis, peptic ulcer disease, glaucoma, cataract, or infection if careful medical monitoring is not ensured,
- •12.History of colorectal cancer,
- •13.History of cancer (other than colorectal) in the last 5 years,
- •14.Therapy with immunomodulators (e.g., azathioprine, 6-mercaptopurine, or methotrexate) within 3 months prior to baseline,
- •15.Treatment with budesonide or other steroids within 4 weeks prior to baseline,
- •16.Treatment with antibiotics within 4 weeks prior to baseline,
- •17.Treatment with anti-diarrhoeal drugs (e.g., loperamide, ispaghula, codeine, and opium), cholestyramine, bulking agents, spasmolytics, bismuth, and probiotics within 2 weeks prior to baseline,
- •18.Known intolerance/hypersensitivity/resistance to the trial drug or drugs of similar chemical structure or pharmacological profile,
- •19.Current or intended pregnancy or breast-feeding,
- •20.Doubt about the patient’s cooperation, e.g. because of addiction to alcohol or drugs,
- •21.Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial,
- •22.Live vaccination within the last 4 weeks before the baseline visit,
- •23.Diagnosis of chickenpox, herpes zoster or measles within the last 3 months before the baseline visit.
研究者
相似试验
进行中（未招募）
不适用
Randomised, double-blind, placebo-controlled, multinational, multi-centre, Phase IIb / III study of the efficacy and safety of three doses of sublingual immunotherapy (SLIT) administered as tablets once daily to patients suffering from grass pollen rhinoconjunctivitisEUCTR2004-001910-15-CZStallergenes S.A.631
进行中（未招募）
1 期
Randomised, double-blind, placebo-controlled, multinational, multi-centre, Phase IIb / III study of the efficacy and safety of three doses of sublingual immunotherapy (SLIT) administered as tablets once daily to patients suffering from grass pollen rhinoconjunctivitisEUCTR2004-001910-15-ESStallergenes S.A.600
进行中（未招募）
1 期
Randomised, double-blind, placebo-controlled, multi-centre trial on the efficacy and safety of budesonide for induction of remission in incomplete microscopic colitisPatients with active incomplete microscopic colitisMedDRA version: 19.0Level: PTClassification code 10056979Term: Colitis microscopicSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2013-001912-31-SEDr. Falk Pharma GmbH106
进行中（未招募）
不适用
Randomised, double-blind, placebo-controlled, multi-centre trial on the efficacy and safety of budesonide for induction of remission in incomplete microscopic colitisPatients with active incomplete microscopic colitisMedDRA version: 14.1Level: PTClassification code 10056979Term: Colitis microscopicSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2013-001912-31-ESDr. Falk Pharma GmbH106
进行中（未招募）
1 期
ovel budenosid suppository in addition to basic therapy with oral mesalazine compared to basic therapy alone for treatment of ulcerative colitisEUCTR2019-003334-16-LVDr. Falk Pharma GmbH360